GlassScriptPhysician profile
Thresa Simon
NPI 1003871989
$2,228.61
in general payments reported to CMS, 2019-2025
25 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $223 · 2021: $252 · 2022: $91.97 · 2023: $213 · 2024: $193 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $369.44 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $278.42 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $256.43 | 2019-2023 | Invega Sustenna, Invega, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $202.41 | 2019-2024 | Trintellix |
| Alkermes, INC. | $192.47 | 2019-2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $179.08 | 2019-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $150.26 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $145.39 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $93.91 | 2024-2025 | Auvelity |
| Lundbeck LLC | $70.63 | 2019-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $63.42 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $61.27 | 2019-2020 | |
| Shire North American Group INC | $27.07 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.67 | 2024 | Caplyta |
| Tris Pharma INC | $24.93 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $24.80 | 2019 | |
| Bioxcel Therapeutics, INC. | $18.95 | 2023 | Igalmi |
| Indivior INC. | $16.49 | 2020 | |
| Abbvie INC. | $14.29 | 2023 | Vraylar |
| Vanda Pharmaceuticals INC. | $12.28 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thresa Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.